Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies

Jacob Ablin, Mary-Ann Fitzcharles, Dan Buskila, Yoram Shir, Claudia Sommer, Winfried Häuser, Jacob Ablin, Mary-Ann Fitzcharles, Dan Buskila, Yoram Shir, Claudia Sommer, Winfried Häuser

Abstract

Objective. Current evidence indicates that there is no single ideal treatment for fibromyalgia syndrome (FMS). First choice treatment options remain debatable, especially concerning the importance of complementary and alternative medicine (CAM) treatments. Methods. Three evidence-based interdisciplinary guidelines on FMS in Canada, Germany, and Israel were compared for their first choice and CAM-recommendations. Results. All three guidelines emphasized a patient-tailored approach according to the key symptoms. Aerobic exercise, cognitive behavioral therapy, and multicomponent therapy were first choice treatments. The guidelines differed in the grade of recommendation for drug treatment. Anticonvulsants (gabapentin, pregabalin) and serotonin noradrenaline reuptake inhibitors (duloxetine, milnacipran) were strongly recommended by the Canadian and the Israeli guidelines. These drugs received only a weak recommendation by the German guideline. In consideration of CAM-treatments, acupuncture, hypnosis/guided imagery, and Tai Chi were recommended by the German and Israeli guidelines. The Canadian guidelines did not recommend any CAM therapy. Discussion. Recent evidence-based interdisciplinary guidelines concur on the importance of treatment tailored to the individual patient and further emphasize the need of self-management strategies (exercise, and psychological techniques).

References

    1. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskeletal Disorders. 2007;8, article 27
    1. Häuser W, Jung E, Erbslöh-Möller B, et al. The German fibromyalgia consumer reports—a cross-sectional survey. BMC Musculoskeletal Disorders. 2012;13, article 74 (Ger).
    1. Marschall U, Arnold B, Häuser W. Treatment and healthcare costs of fibromyalgia syndrome in Germany: analysis of the data of the barmer health insurance BEK from 2008-2009. Schmerz. 2011;25(4):402–404, 406–410. (Ger).
    1. Lachaine J, Beauchemin C, Landry P-A. Clinical and economic characteristics of patients with fibromyalgia syndrome. Clinical Journal of Pain. 2010;26(4):284–290.
    1. Häuser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome—a systematic review. European Journal of Pain. 2010;14(1):5–10.
    1. National Center for Complementary and Alternative Medicine. What is complementary and alternative medicine? 2013, .
    1. Oxford Center of Evidence Based Medicine. Levels of evidence (march 2009) .
    1. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) Program for national disease management guidelines. Report of Methods. 2010;(4) .
    1. Fitzcharles MA, Ste-Marie PA, Goldenberg DL, et al. 2012 Canadian guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Research&Management. 2013;18(3):119–126.
    1. Eich W, Häuser W, Arnold B, et al. Fibromyalgia syndrome. general principles and coordination of clinical care and patient education. Schmerz. 2012;26(3):268–275. (Ger).
    1. Sommer C, Häuser WH, Alten R, et al. Drug therapy of fibromyalgia syndrome. systematic review, meta-analysis and guideline. Schmerz. 2012;26(3):297–310. (Ger).
    1. Köllner V, Häuser W, Klimczyk K, et al. Psychotherapy for patients with fibromyalgia syndrome. systematic review, meta-analysis and guideline. Schmerz. 2012;26(3):291–296. (Ger).
    1. Winkelmann A, Häuser W, Friedel E, et al. Physiotherapy and physical therapies for fibromyalgia syndrome. systematic review, meta-analysis and guideline. Schmerz. 2012;26(3):276–286. (Ger).
    1. Langhorst J, Häuser W, Bernardy K, et al. Complementary and alternative therapies for fibromyalgia syndrome. systematic review, meta-analysis and guideline. Schmerz. 2012;26(3):311–317. (Ger).
    1. Arnold B, Häuser W, Arnold M, et al. Multicomponent therapy of fibromyalgia syndrome. systematic review, meta-analysis and guideline. Schmerz. 2012;26(3):287–290. (Ger).
    1. Ablin JN, Amital H H, Ahrenfeld M, et al. Guidelines for the diagnosis and treatment of the fibromyalgia syndrome. Harefuah, 2013, (Hebrew)
    1. Schaefert R, Hausteiner-Wiehle C, Häuser W, Ronel J, Herrman M, Henningsen P. Non-specific, functional, and somatoform bodily complaints. Deutsches Arzteblatt International. 2012;109(47):803–813.
    1. Pioro-Boisset M, Esdaile JM, Fitzcharles MA. Alternative medicine use in fibromyalgia syndrome. Arthritis Care and Research. 1996;9(1):13–17.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir